SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Mutation C938A

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 A Phase II Trial of Induction Chemotherapy With ND-420, Cisplatin and Fluorouracil Followed by Surgery in the Treatment of Patients With Localized Squamous Cell Carcinoma of the Esophagus

Investigator will assign 53 patients who had been histologically proven localized squamous cell carcinoma of esophagus to receive the induction chemotherapy regimen of ND-420 50 mg/m2 on day 1, cisplatin 70 mg/m2 on day1, plus fluorouracil 700 mg/m2 daily, day1 to day4, every 3 weeks for 2 cycles and then followed by surgical resection. The successful rate of complete treatment per protocol and complete resection will be the primary variant to evaluate in our study.

NCT02017600 Localized Squamous Cell Carcinoma of the Esophagus Drug: ND-420 Procedure: Surgery Drug: Cisplatin Drug: fluorouracil
MeSH: Carcinoma Carcinoma, Squamous Cell Esophageal Neoplasms Esophageal Squamous Cell Carcinoma
HPO: Carcinoma Esophageal neoplasm Squamous cell carcinoma

the correlation between clinical outcomes and the potential predictive genomic biomarkers(B-tubulin mutation, p53-Arg 72Pro, Bcl2-C938A, MDR1-C3435T polymorphism, TNFRSF1B-1466, GSTP1-l105V, CYP1B1, TS-5'UTR) for tumor response. --- C938A ---

Primary Outcomes

Measure: the R0 resection rate of participants

Time: up to three months

Secondary Outcomes

Measure: the response rate (RECIST) of participants

Time: up to three months

Measure: Number of participants with adverse events as a measure of safety and tolerability

Time: up to one year

Measure: the population pharmacokinetic parameters (Cmax, AUC... )of ND-420 in the participants

Time: 0, 30min, 1hr of ND-420 infusion. selected randomly form one of 3hr, 7hr, 11hr and 23hr after the end of ND-420 infusion.

Measure: the correlation between clinical outcomes and the potential predictive genomic biomarkers(B-tubulin mutation, p53-Arg 72Pro, Bcl2-C938A, MDR1-C3435T polymorphism, TNFRSF1B-1466, GSTP1-l105V, CYP1B1, TS-5'UTR) for tumor response

Time: up to one year

Measure: 1-year survival rate of participants

Time: up to one year

Measure: pathologic complete response rate of participants

Time: up to one year

Measure: 1-year progression free survival rate of participants

Time: up to one year

Measure: 1-year overall survival rate of participants

Time: up to one year


HPO Nodes


Squamous cell carcinoma
Genes 79
COL7A1 WNT10A CDKN2A GJB6 FDPS LZTS1 GTF2H5 TERT NLRP1 ERCC5 NUTM1 ERCC2 RSPO1 LAMA3 TMC8 CTSC ING1 RECQL4 GJB2 ERCC2 TGFBR2 ERCC4 LAMC2 LAMB3 MPLKIP TARS1 ERCC3 XPC DOCK8 BLM NTHL1 TYR PSENEN WRAP53 GTF2E2 IL7 RNF6 SLC17A9 TNFRSF10B DKC1 POLH RECQL4 BLM BRD4 KRT5 TMC6 TERC ERCC2 SASH1 WNT10A MC1R CIB1 SLC45A2 MVD WRN KRT14 DDB2 RNF113A DCC FERMT1 TYR COL7A1 ERCC3 ERCC3 COL7A1 MMP1 COL7A1 GJB2 SLX4 MMP1 LMNA MVK TINF2 WWOX GJB2 OCA2 CIB1 POLH STAT1
Carcinoma
Genes 16
POLE MSH2 DKC1 SMARCA4 NLRP1 POLD1 CDKN1B MLH1 RSPO1 FGFR3 BCL10 APC STK11 PTEN APC KIT
Esophageal neoplasm
Genes 21
RHBDF2 PDGFRA FH KIT RAD21 CTHRC1 DLEC1 WWOX STK11 ASCC1 TGFBR2 SDHB KIT RNF6 APC SDHA SDHC RHBDF2 STAT1 MSR1 APC